At Clariness, we work on the premise that no two clinical trials are the same. While others fixate on the quantity of patient referrals, we go to great lengths to understand the target indication, how it impacts the study population and refer only the patients and volunteers that meet our clients’ exacting criteria.
For each individual study we support, we create a detailed targeting approach based on the needs of our partners, various feedback meetings about the study procedure, and the specific patient population of our target indication. This approach has allowed us to successfully support more than 1,200 clinical trials across all major indications, reaching the required number of patients either on time, or ahead of schedule.
On our therapy pages below, you will find a summary of the latest research on patient recruitment within each indication, learn more about our indication-specific experience and expertise, and how we support decentralized clinical trials (DCTs), trial diversity and more.
Knowing asthma impacts patients of all ages, we have developed techniques to enroll patients of all ages, one study recruited patients from 4 to 80 years old.
We have performed patient recruitment for over 20 atopic dermatitis trials, from Phase I to IV (including both adult and adolescent patients).
Only 5% of the patients with breast cancer take parts in clinical trials. Having successfully supported 15 breast cancer trials in recent years, we know how to close this gap.
With experience of 30+ studies from Phase I to Phase III, we have verified COPD study feasibility and delivered documentation, protocols and of course, patients.
Everything about patient recruitment, retention, and dropout in COVID19-clinical trials, locally and across the globe.
We have supported 50+ studies from Phase I to Phase III across the globe. In a single campaign, we attracted over 3 million visits to trial-specific landing pages.
Depression is estimated to affect 264 million people worldwide, yet clinical trial organizers still face major problems with recruiting patients for depression studies. Our patient-centric digital approach solves this problem.